Last reviewed · How we verify
cross-linked hyaluronic acid
cross-linked hyaluronic acid is a Viscosupplement Small molecule drug developed by Taipei Medical University. It is currently FDA-approved for Osteoarthritis of the knee, Joint pain and dysfunction. Also known as: physical therapy.
Cross-linked hyaluronic acid forms a viscoelastic gel that lubricates and cushions joints by mimicking natural synovial fluid.
Cross-linked hyaluronic acid forms a viscoelastic gel that lubricates and cushions joints by mimicking natural synovial fluid. Used for Osteoarthritis of the knee, Joint pain and dysfunction.
At a glance
| Generic name | cross-linked hyaluronic acid |
|---|---|
| Also known as | physical therapy |
| Sponsor | Taipei Medical University |
| Drug class | Viscosupplement |
| Modality | Small molecule |
| Therapeutic area | Orthopedics / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Cross-linked hyaluronic acid is a biopolymer derivative that integrates into the joint space to restore viscosity and elasticity of synovial fluid. It provides mechanical lubrication and shock absorption while potentially stimulating endogenous hyaluronic acid production and reducing inflammatory mediators in the joint microenvironment.
Approved indications
- Osteoarthritis of the knee
- Joint pain and dysfunction
Common side effects
- Injection site pain or swelling
- Transient joint effusion
- Local inflammation
Key clinical trials
- Clinical Investigation on Lips Treated With HA-filler (NA)
- Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? (NA)
- A Post-market-clinical Follow-up Investigation of Safety and Performance by Decoria® Voluma (NA)
- Non-Surgical Treatment of Periodontitis With Adjunctive Sodium Hypochlorite/Amino Acids and Cross-Linked Hyaluronic Acid (NA)
- Filler Post Market Survey (FIPS)
- A Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine (NA)
- Influence of Hyaluronic Acid in the Healing of Palatal Donor Sites During Free Gingival Graft Procedures (NA)
- Efficacy and Safety of BtH Body 2.2% (Injectable Hyaluronic Acid) in Volumizing and Contouring Large Areas of the Body: Prospective Clinical Investigation. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cross-linked hyaluronic acid CI brief — competitive landscape report
- cross-linked hyaluronic acid updates RSS · CI watch RSS
- Taipei Medical University portfolio CI
Frequently asked questions about cross-linked hyaluronic acid
What is cross-linked hyaluronic acid?
How does cross-linked hyaluronic acid work?
What is cross-linked hyaluronic acid used for?
Who makes cross-linked hyaluronic acid?
Is cross-linked hyaluronic acid also known as anything else?
What drug class is cross-linked hyaluronic acid in?
What development phase is cross-linked hyaluronic acid in?
What are the side effects of cross-linked hyaluronic acid?
Related
- Drug class: All Viscosupplement drugs
- Manufacturer: Taipei Medical University — full pipeline
- Therapeutic area: All drugs in Orthopedics / Rheumatology
- Indication: Drugs for Osteoarthritis of the knee
- Indication: Drugs for Joint pain and dysfunction
- Also known as: physical therapy